ZMUni Compliance Centre

  On April 30, 2025, China National Medical Products Administration (NMPA) issued a new supplementary testing method: BJH 202501 Determination of Meprednisone in Cosmetics.   This method outlines the qualitative and quantitative analysis of Meprednisone (CAS No.1247-42-3) in various categories of cosmetics, such as liquid (water, oil), cream and milk, gel, and wax-based products.   Meprednisone is a type of glucocorticoid, with common derivatives including methylprednisolone acetate and related compounds. Glucocorticoids and their by-products are known for their skin-lightening and anti-allergic properties. When added to cosmetics, these substances can significantly enhance effects such as acne reduction, anti-inflammation, pigmentation fading, and whitening.   However, prolonged use may

On April 18, 2025, China's General Administration of Customs (GACC) published its list of non-compliant imported food products for March 2025. A total of 231 batches from 40 countries and regions were denied entry, marking a 13.5% decrease compared to the previous month and an 8.0% decline year-on-year.   Significantly, this is the fourth consecutive month of decline since the number of rejected imports peaked in November 2024. Analysts suggest the downward trend may be influenced by external factors, including adjustments to U.S. tariff policies.   The majority of non-compliant imports came from the U.S. (23%), Spain ranked second (9.1%), Brazil (8.2%), and

        Recently, South Korea's National Assembly officially passed the Synthetic Biology Promotion Act, making it the first country in the world to enact legislation specifically dedicated to the field of synthetic biology. The law will come into effect in 2026, following cabinet approval and promulgation, after a one-year preparation period. To ensure smooth implementation, the South Korean government plans to simultaneously advance supplementary legislation, including enforcement decrees and relevant guidelines.   Synthetic biology is regarded as a cutting-edge field that integrates artificial intelligence, big data, and life sciences. It has wide-ranging applications in areas such as vaccine

If you would like to gain a clearer and more comprehensive understanding of the management of cosmetic ingredients in China, we invite you to explore our previous article, Cosmetic Ingredients in China: Your Guide to the Latest Compliance Requirements. It provides helpful insights to build a solid foundation before diving into this topic.     From April 22 to 28, 2025, 7 new cosmetic ingredients were notified with the China National Medical Products Administration (NMPA). They include:   The technical requirements for the 7 new cosmetic ingredients mentioned above have not been disclosed, and they have not yet entered the safety monitoring period.  

On April 24, 2025, China's State Administration for Market Regulation (SAMR) issued a public consultation on the draft "Catalog of Permitted Health Claims for Health Foods: Aids in Maintaining Joint Health." Stakeholders are invited to submit their feedback by June 2, 2025   This marks the first new health function proposed to be included in the official health claim catalog since the issuance of the “Implementation Rules for the Evaluation of New Health Functions and Product Technologies of Health Foods (Trial)”.   The newly proposed function, “aids in maintaining joint health,” encompasses several specific benefits, including alleviating joint pain and

  To help overseas companies stay up to date with cosmetic ingredient trends in China, ZMUni Compliance Centre will publish a regular series on New Cosmetic Ingredient (NCI) notifications. We hope this provides valuable insights for ingredient suppliers and brands looking to enter the Chinese market.     From April 11 to 21, 2025, 2 new cosmetic ingredients were notified with the China National Medical Products Administration (NMPA). They include: Ingredient Name in CN Notification No. Notifier in CN 透明质酸水杨酸酯钠 202500035 华熙生物科技股份有限公司 N-乙酰基-丝氨酰-脯氨酰-缬氨酰-异亮氨酰-缬氨酰-脯氨酰胺 202500036 北京茂思商贸有限公司   The technical requirements for the 2 new cosmetic ingredients mentioned above have not been disclosed, and they have not

To help overseas companies stay up to date with cosmetic ingredient trends in China, ZMUni Compliance Centre will publish a regular series on New Cosmetic Ingredient (NCI) notifications. We hope this provides valuable insights for ingredient suppliers and brands looking to enter the Chinese market.     From April 1st to 10th, 2025, 4 new cosmetic ingredients were notified with the China National Medical Products Administration (NMPA). They include: Ingredient Name in CN&EN Notification No. Notifier in CN 乙酰基三肽-30 瓜氨酸 Acetyl Tripeptide 30 Citrulline 202500031 深圳市护家科技有限公司 红景天苷 Salidroside 202500032 上海华茂药业有限公司 昙花（Epiphyllum oxypetalum）愈伤组织提取物 Epiphyllum Oxypetalum Callus Extract 202500033 杭州拾光欣雅有限公司 苦丁茶（ILEX KUDINGCHA）叶提取物 ILEX KUDINGCHA Leaf Extract 202500034 广州袋鼠妈妈科技创新研究有限公司

      On April 10, 2025, China's National Institutes for Food and Drug Control (NIFDC) released the Information on the Use of Some Ingredients Included in the Index of International Cosmetic Safety Assessment Data, along with a corresponding Q&A.   Developed in response to industry needs, this document builds upon the Ingredient Usage Information of Marketed Products released by NIFDC on February 9, 2025. It focuses on ingredients listed in the Index of International Cosmetic Safety Assessment Data that are frequently used in registered or notified cosmetics in China, particularly those lacking definitive safety conclusions or subject to usage restrictions. The update